Policy & Regulation
PreveCeutical partners with Veristat to prepare clinical trials of Sol-Gel COVID-19 programme
5 August 2020 -

Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) said on Tuesday that it is preparing to launch clinical trials of cannabinoid sol-gel with the possibility of reducing the transmission of COVID-19 under an expected coronavirus treatment acceleration programme (CTAP).

In conjunction with the COVID-19 sol-gel clinical programme, the company said it has retained Veristat, a global clinical research organization , based in Massachusetts, USA, to assist with planning, designing and developing the clinical trial process and writing the required protocols

However, the company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 at this time.

Login
Username:

Password: